KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Invested Capital (2019 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Invested Capital for 7 consecutive years, with 0.09% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital rose 26.0% to 0.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.09% through Dec 2025, up 26.0% year-over-year, with the annual reading at 0.08% for FY2025, 25.0% up from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.09% at Xenon Pharmaceuticals, up from 0.56% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.07% in Q1 2021, with the low at 0.56% in Q3 2025.
  • Average Return on Invested Capital over 5 years is 0.25%, with a median of 0.24% recorded in 2024.
  • Peak annual rise in Return on Invested Capital hit 26bps in 2025, while the deepest fall reached -26bps in 2025.
  • Over 5 years, Return on Invested Capital stood at 0.2% in 2021, then rose by 8bps to 0.18% in 2022, then tumbled by -45bps to 0.26% in 2023, then tumbled by -34bps to 0.35% in 2024, then skyrocketed by 74bps to 0.09% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.09%, 0.56%, and 0.47% for Q4 2025, Q3 2025, and Q2 2025 respectively.